NYC Records 1st Major Allergic Reaction Out Of 30,000-Plus Vaccine Shots
New York City registered the first “significant allergic reaction” in a health care worker who took Pfizer on Wednesday. The first adverse reaction received from more than 30,000 shots to date.
The worker has been treated and is in a stable state, city officials said. Allergic reactions to Pfizer have been reported in clinical trials. And after the FDA granted emergency use authorization earlier this month. But remains uncommon.
Health authorities say they are actively investigating accounts of more significant side effects in coordination with the CDC. In the meantime, vaccination delivery will continue to ensure that frontline employee. And nursing home patients and personnel are safe from the infection, health authorities said in a statement.
No specific information on the allergic reaction of the injured worker was readily available. The City did not reveal any further detail on the case at Mayor Bill de Blasio’s Wednesday COVID meeting, citing secrecy rules.
“Vaccines, including the COVID vaccine, are safe in general,” said Dr. Dave Chokshi, City Health Commissioner, during the meeting. “For the vast majority of people who have allergies, the COVID vaccine will be safe and effective for you.”
Chokshi said people who have a history of allergic reactions to some form of vaccination or injection should have discussions with their doctors before obtaining the COVID-19 vaccine.
Rare allergic reactions have been reported in Britain. It was before introducing Pfizer/BioNTech in the United States. It has since reported similar, rare reactions. Three of them were health staff in Alaska.
Earlier this week, an official with the National Institute of Allergy and Infectious Diseases told CNBC that the U.S. investigates whether specific individuals have severe allergic reactions after taking the shots.
The research, which is still in the early planning stages, is planned to involve “several hundred” people with a history of severe allergic reactions, Alkis Togias, Director of the NIAID Allergy, Asthma, and Airway Biology Division, told CNBC. The people who obtained Pfizer’s shot documented rare reactions. The study may look at vaccines produced by Pfizer and Moderna.
